These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29057545)

  • 1. Modelling incremental benefits on complications rates when targeting lower HbA
    Mostafa SA; Coleman RL; Agbaje OF; Gray AM; Holman RR; Bethel MA
    Diabet Med; 2018 Jan; 35(1):72-77. PubMed ID: 29057545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
    Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
    Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
    Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
    Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
    Dziuba J; Alperin P; Racketa J; Iloeje U; Goswami D; Hardy E; Perlstein I; Grossman HL; Cohen M
    Diabetes Obes Metab; 2014 Jul; 16(7):628-35. PubMed ID: 24443793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates.
    Mostafa SA; Coleman RL; Agbaje OF; Gray AM; Holman RR; Bethel MA
    J Diabetes Complications; 2019 Jan; 33(1):69-74. PubMed ID: 30361000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study).
    Laiteerapong N; Ham SA; Gao Y; Moffet HH; Liu JY; Huang ES; Karter AJ
    Diabetes Care; 2019 Mar; 42(3):416-426. PubMed ID: 30104301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome in type 1 diabetes and its association with diabetes complications.
    Lee AS; Twigg SM; Flack JR
    Diabet Med; 2021 Feb; 38(2):e14376. PubMed ID: 32738821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Engel SS; Green JB; Huang Z; Josse RG; Kaufman KD; Standl E; Suryawanshi S; Van de Werf F; McGuire DK; Peterson ED; Holman RR;
    Diabetes Care; 2017 Apr; 40(4):494-501. PubMed ID: 28057693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.
    Chen J; Alemao E; Yin D; Cook J
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():33-42. PubMed ID: 18435672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.
    Ceriello A; Lucisano G; Prattichizzo F; La Grotta R; Franzén S; Svensson AM; Eliasson B; Nicolucci A
    Cardiovasc Diabetol; 2022 Jan; 21(1):13. PubMed ID: 35073913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes Complications at Presentation and One Year by Glycated Haemoglobin at Diagnosis in a Multiethnic and Diverse Socioeconomic Population: Results from the South London Diabetes Study.
    Azam M; Marwood L; Ismail K; Evans T; Sivaprasad S; Winkley K; Amiel SA
    J Diabetes Res; 2015; 2015():587673. PubMed ID: 26090473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declining Trends of Cardiovascular-Renal Complications and Mortality in Type 2 Diabetes: The Hong Kong Diabetes Database.
    Luk AOY; Hui EMT; Sin MC; Yeung CY; Chow WS; Ho AYY; Hung HF; Kan E; Ng CM; So WY; Yeung CK; Chan KS; Chan KW; Chan PF; Siu SC; Tiu SC; Yeung VTF; Chan JCN; Chan FWK; Cheung C; Cheung NT; Ho ST; Lam KSL; Yu LWL; Chao D; Lau IT
    Diabetes Care; 2017 Jul; 40(7):928-935. PubMed ID: 28490423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, study design and methodology of the LANDMARC trial: a 3-year, pan-India, prospective, longitudinal study to assess management and real-world outcomes of diabetes mellitus.
    Das AK; Mithal A; Kumar KMP; Unnikrishnan AG; Kalra S; Thacker H; Sethi B; Ghosh R; Mathew A; Chodankar D; Mohanasundaram S; Menon SK; Trivedi C; Naqvi M; Kanade V; Salvi V; Chatterjee G; Rais N; Wangnoo SK; Chowdhury S; Zargar AH; Joshi S
    Diabet Med; 2020 May; 37(5):885-892. PubMed ID: 31691356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct trajectories of HbA
    Rathmann W; Schwandt A; Hermann JM; Kuss O; Roden M; Laubner K; Best F; Ebner S; Plaumann M; Holl RW;
    Diabet Med; 2019 Nov; 36(11):1468-1477. PubMed ID: 31392761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Davis TME; Mulder H; Lokhnygina Y; Aschner P; Chuang LM; Raffo Grado CA; Standl E; Peterson ED; Holman RR;
    Diabetes Obes Metab; 2018 Jun; 20(6):1427-1434. PubMed ID: 29405540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial.
    ; Gilbert RE; Mann JF; Hanefeld M; Spinas G; Bosch J; Yusuf S; Gerstein HC
    Diabetologia; 2014 Jul; 57(7):1325-31. PubMed ID: 24771090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.